Bridgewater Associates’s Halozyme HALO Stock Holding History
Bought
Maintained
Sold
Other funds holding HALO
Bridgewater Associates's HALO Position: Q2 2026 in Review
Bridgewater Associates reduced its Halozyme (HALO) stake by 9.4% in Q2 2026, selling an estimated $3.29M and leaving 463,146 shares worth $36.3M. The position accounts for 0.15% of the portfolio, ranked #113.
Bridgewater Associates first reported a position in HALO in Q2 2023 and has held it in 10 quarters since. The position peaked at $37.8M in Q4 2025. 668 funds tracked by Wall St. Rank hold HALO as of Q2 2026.
- Bridgewater Associates held 463,146 shares of Halozyme worth $36.3M as of Q2 2026.
- Bridgewater Associates sold 48,283 Halozyme shares in Q2 2026, an estimated $3.29M.
- Halozyme made up 0.15% of Bridgewater Associates's portfolio in Q2 2026, its #113 holding.
- Bridgewater Associates first reported a position in Halozyme in Q2 2023 and has held it in 10 quarters since.
- Bridgewater Associates's Halozyme position peaked at $37.8M in Q4 2025.
- 668 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.
Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.